Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses

被引:26
|
作者
Chow, Edwin Chiu Yuen [1 ,2 ]
Talattof, Arjang [1 ,2 ]
Tsakalozou, Eleftheria [1 ,2 ]
Fan, Jianghong [1 ,2 ]
Zhao, Liang [1 ,2 ]
Zhang, Xinyuan [1 ,2 ]
机构
[1] US FDA, Div Quantitat Methods & Modeling, Off Res & Stand, Off Gener Drugs, Silver Spring, MD 20993 USA
[2] 10903 New Hampshire Ave,Bldg 75,Room 4690, Silver Spring, MD 20993 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
Biopharmaceutics Classification System (BCS); excipients; gastrointestinal transporters; oral drug absorption; PBPK modeling; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; PEPTIDE TRANSPORTER PEPT1; COMMONLY USED EXCIPIENTS; P-GLYCOPROTEIN; CREMOPHOR EL; CACO-2; CELLS; BIOAVAILABILITY; PERMEABILITY; SURFACTANTS; METABOLISM;
D O I
10.1208/s12248-016-9964-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C-max and AUC(0-t) of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C-max more than AUC(0-t) for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C-max and AUC(0-t). Reducing or increasing influx and efflux transporter activity might likely affect C-max and AUC(0-t) of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
引用
收藏
页码:1500 / 1511
页数:12
相关论文
共 50 条
  • [31] PREDICTION OF DRUG DISPOSITION USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING APPROACH: VENLAFAXINE EXTENDED RELEASE FORMULATION.
    Isikwei, E.
    Reid, J.
    Cunningham, J.
    Krieger, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S55 - S56
  • [32] Physiologically based pharmacokinetic (PBPK) modeling of BDE-209 following oral exposure in Chinese population
    Zhang, Zhichun
    Hu, Man
    Xuan, Dongliang
    Wu, Linying
    Zhang, Yanfei
    He, Gengsheng
    Zhou, Ying
    FOOD AND CHEMICAL TOXICOLOGY, 2022, 169
  • [33] ANTIBODY-DRUG CONJUGATES (ADCS) DRUG INTERACTIONS CAN BE PREDICTED USING A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING APPROACH
    Mukadam, Sophie
    Samineni, Divya
    Wong, Harvey
    Shen, Ben-Quan
    Lu, Dan
    Girish, Sandhya
    Hop, Cornelis
    Jin, Yan Jin
    Li, Chunze
    Chen, Yuan
    DRUG METABOLISM REVIEWS, 2015, 47 : 118 - 118
  • [34] Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
    Teerachat Saeheng
    Kesara Na-Bangchang
    Juntra Karbwang
    European Journal of Clinical Pharmacology, 2018, 74 : 1365 - 1376
  • [35] Maximizing the Impact of Physiologically Based Oral Absorption Modeling and Simulation
    Chung, John I.
    Kelly, Ron C.
    Wahlstrom, Jan
    Wu, Benjamin
    Wu, Tian
    Alvarez-Nunez, Fernando
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (03) : 734 - 737
  • [36] Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute
    Smits, Anne
    De Cock, Pieter
    Vermeulen, An
    Allegaert, Karel
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (01) : 25 - 34
  • [37] Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective
    Arian Emami Riedmaier
    Kevin DeMent
    James Huckle
    Phil Bransford
    Cordula Stillhart
    Richard Lloyd
    Ravindra Alluri
    Sumit Basu
    Yuan Chen
    Varsha Dhamankar
    Stephanie Dodd
    Priyanka Kulkarni
    Andrés Olivares-Morales
    Chi-Chi Peng
    Xavier Pepin
    Xiaojun Ren
    Thuy Tran
    Christophe Tistaert
    Tycho Heimbach
    Filippos Kesisoglou
    Christian Wagner
    Neil Parrott
    The AAPS Journal, 22
  • [38] Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective
    Riedmaier, Arian Emami
    DeMent, Kevin
    Huckle, James
    Bransford, Phil
    Stillhart, Cordula
    Lloyd, Richard
    Alluri, Ravindra
    Basu, Sumit
    Chen, Yuan
    Dhamankar, Varsha
    Dodd, Stephanie
    Kulkarni, Priyanka
    Olivares-Morales, Andres
    Peng, Chi-Chi
    Pepin, Xavier
    Ren, Xiaojun
    Thuy Tran
    Tistaert, Christophe
    Heimbach, Tycho
    Kesisoglou, Filippos
    Wagner, Christian
    Parrott, Neil
    AAPS JOURNAL, 2020, 22 (06):
  • [39] Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
    Saeheng, Teerachat
    Na-Bangchang, Kesara
    Karbwang, Juntra
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (11) : 1365 - 1376
  • [40] Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics
    Leeds, Janet M.
    Ke, Alice
    Yeo, Karen Rowland
    Curnutte, John T.
    Conley, Pamela B.
    BLOOD, 2017, 130